Interferon-gamma (INF-gamma) release test can detect cutaneous adverse effects to statins

Int J Dermatol. 2009 Dec;48(12):1370-5. doi: 10.1111/j.1365-4632.2008.03896.x.

Abstract

Background: An increasing number of cutaneous adverse effects are being reported as use of statins becomes more widespread. A study was undertaken to establish the relationship between statin and a cutaneous reaction by the in vitro interferon-gamma (INF-gamma) release test.

Methods: The lymphocytes of 20 patients with suspected drug-induced skin reaction were incubated with and without the drug. The level of INF-gamma from the supernatant was measured by enzyme-linked immunosorbent assay (ELISA), and the increase calculated.

Results: Response was positive in 27 (21.43%) of the 126 drugs. Statin was the only drug with a positive response in 80% of those cases. Nine of 20 patients (45.0%) had complete resolution after discontinuation of the drug; 6 (30.0%) who replaced one drug by another statin had partial or no resolution; and 5 (20.0%) had no resolution despite cessation of statins of all kinds.

Conclusion: A positive INF-gamma release test was found in patients who developed skin reactions while taking statins; the test's reliability was strengthened by prompt improvement following elimination of the suspected drug in the majority of patients.

MeSH terms

  • Aged
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Interferon-gamma / analysis*
  • Male
  • Middle Aged
  • Skin Diseases / chemically induced*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Interferon-gamma